Original Research Article

A Retrospective Study to Assess the Correlation of Hs Troponin I & Uric Acid in Patients of Myocardial Infarction

Rolly Bharty[1], Anand[2]

[1]Assistant Professor and Head, Department of Biochemistry, Jawaharlal Nehru Medical College and Hospital, Bhagalpur, Bihar, India

[2]Tutor, Department of Biochemistry, Jawaharlal Nehru Medical College and Hospital, Bhagalpur, India

Abstract

Aim: The aim of the present study was to assess the Correlation of Hs Troponin I & Uric Acid in patients of Myocardial Infarction.

Methods: 200 patients who came to cardiac emergency in the Department of Biochemistry, Jawahar Lal Nehru Medical College, Bhagalpur, Bihar, India for one year. Serum samples were taken for Hs Troponin I and Uric Acid for patients of Myocardial Infarction and run on VITROS 5600/7600 which is based on dry chemistry.

Results: Among the 200 patients of more than 40 years of age 120 were males & 80 were females. For both males & females age mean & SD was 60.6 ± 11.72 and 58.6 ± 12.70. For Hs Trop I males were 22.78 ± 46.84 & females 15.75 ± 54.56. For uric acid for males were 6.534 ± 3.750 & for females 6.316 ± 1.860. For Hs Trop I males were 22.78 ± 46.84 & females 15.75 ± 54.56. For uric acid for males were 6.534 ± 3.750 & for females 6.316 ± 1.860. Therefore Hs Trop I & uric acid were both significant when compared with age P value was 0.0040. Whereas when compared with sex that is male and female to both Hs Trop I and uric acid then Hs Trop I was more significant with P value 0.0001.

Conclusion: In acute MI, patients with hyperuricemia had higher mortality. Serum uric acid levels correlated with Killip classification in acute MI. Serum uric acid can be used as a marker of short term mortality in patients. Hyperuricemia is an indicator of poor prognosis in acute MI. Uric acid is an economical biomarker that is readily, quickly and reliably obtainable, it can be one of the predictable prognostic indicator in acute Myocardial Infarction.

Keywords: Hs troponin I, Serum uric acid, Myocardial Infarction

Introduction

Chest pain is a common complaint for patients presenting to the emergency department (ED). In the United States, more than 8 million patients presented to ED for chest pain in 2019. [1] While chest pain accounts for approximately 10% of emergency department visits, only 10 to 20% of chest pain is diagnosed as cardiac chest pain [2], with a majority being attributed to a multitude of other diagnoses. Differentiating chest pain that originates from cardiac ischemia, such as acute coronary syndrome (ACS), remains a diagnostic dilemma, as patients may present atypically. Conditions such as pulmonary embolism, aortic dissection, or pneumothorax may mimic ACS and present with symptoms such as chest pain and shortness of breath. [3] At time of presentation, approximately 80% of patients with chest pain do not have a clear diagnosis of ACS [4], with a further need to be monitored and worked up while in the emergency department or emergency observation units. While clinical evaluation of patients and repeated electrocardiograms (ECG) are essential, these alone are not enough to reliably rule out ACS, and have to be used in conjunction with other investigations. [5]

The use of cardiac biomarkers, especially cardiac troponin, remains a cornerstone in the diagnosis of myocardial infarction. [6] The troponin complex consists of three subunits (troponin I, T, and C), and plays a vital role in regulating cardiac excitation and contraction. [7] In the setting of myocardial infarction, both troponin I and T are released from the damaged myocardium. [8] Conventional troponin assays are limited by their low sensitivities at the time of patient presentation, due to delay in the increase in circulating levels of troponin, requiring repeated testing 6–9 h after presentation [9] and are deemed as unlikely to be cost-effective. [10] With

the introduction of high-sensitivity troponin, new protocols were generated to help in the risk stratification of patients presenting to the emergency department with chest pain or symptoms suggestive of cardiac ischemia for myocardial infarction as quickly as within one to two hours. [11,12]

The aim of the present study was to assess the Correlation of Hs Troponin I & Uric Acid in patients of Myocardial Infarction.

Materials and Methods

200 patients who came to cardiac emergency in the Department of Biochemistry, Jawahar Lal Nehru Medical College, Bhagalpur, Bihar, India for one year. Serum samples were taken for Hs Troponin I and Uric Acid for patients of Myocardial Infarction and run on VITROS 5600/7600 which is based on dry chemistry.

Results

Table 1: Distribution of Hs Tropi and uric acid in age and observed

Parameters	Male	Female	P Value
	Hs Tropi	Uric acid	
	Mean± SD	Mean± SD	
Age	60.6±11.72	58.6±12.70	1
Observed	21.58±52.58	6.374±3.180	0.0040

Among the 200 patients of more than 40 years of age 120 were males & 80 were females. For both males & females age mean & SD was 60.6±11.72 and 58.6±12.70.

Table 2: Distribution of Hs Tropi and uric acid in male and female

Parameters	Male	Female	P Value
	Mean± SD	Mean± SD	
HS Tropi	22.78±46.84	15.75±54.56	0.0001
Uric acid	6.534±3.750	6.316±1.860	0.634

For Hs Trop I males were 22.78±46.84 & females 15.75±54.56. For uric acid for males were 6.534±3.750 & for females 6.316±1.860.

Therefore Hs Trop I & uric acid were both significant when compared with age P value was 0.0040.Whereas when compared with sex that is male and female to both Hs Trop I and uric acid then Hs Trop I was more significant with P value 0.0001. (Table 1 and Table 2)

Discussion

The Global burden of disease Study reported that in 1990 there were 5.2 million deaths from cardiovascular diseases in economically developed countries and 9.1 million deaths from the same causes in developing countries. [13] The prevalence of CAD in India increased from 1% in 1960 to 9.7% in 1995 in urban populations & in rural population it is most doubled in past decade. [14] There has been growing interest in the link between uric acid levels, xanthine oxidoreductase and cardiovascular disease. Previous studies have reported that a high concentration of uric acid is a strong marker of an unfavorable prognosis of moderate to severe heart failure and cardiovascular disease. [15,16] Uric acid levels may be elevated in heart failure and provide important prognostic information. [17]

Among the 200 patients of more than 40 years of age 120 were males & 80 were females. For both males & females age mean & SD was 60.6±11.72 and 58.6±12.70. For Hs Trop I males were 22.78±46.84 & females 15.75±54.56. For uric acid for males were 6.534±3.750 & for females 6.316±1.860. For Hs Trop I males were 22.78±46.84 & females 15.75±54.56. For uric acid for males were 6.534±3.750 & for females 6.316±1.860. Therefore Hs Trop I & uric acid were both significant when compared with age P value was 0.0040.Whereas when compared with sex that is male and female to both Hs Trop I and uric acid then Hs Trop I was more significant with P value 0.0001. Serum uric acid and MI has been debated with conflicting results in previous studies. The AMORIS study [18] and the Rotterdham study [19] have been demonstrated a significant association between Serum uric acid & MI. In contrast, the Tromso study [20] and the NHANES (National Health and Nutrition Examination Survey) III study [21] have failed to establish an independent association between Serum uric acid and MI. First, Serum uric acid is a product of xanthine oxidoreductase, which is known to be one of the most important sources of reactive oxygen species, High Serum uric acid is therefore associated with increased vascular endothelial function, vascular smooth muscle cell proliferation and oxidative stress thereby increasing the risk of MI and all-cause mortality. [22,23] Second, high Serum uric acid exerts a plethora of deleterious effects in cells and thus may be directly involved in the pathophysiological characteristics of MI and all-cause mortality. [24] Third, high Serum

uric acid is correlated with almost all known cardiovascular risk factors, such as metabolic syndrome [25] and chronic kidney disease thus, a higher level of Serum uric acid may be seen as correlation of cardiovascular risk or an epiphenomenon of coexisting cardiometabolic risk factor.

While the usage of high-sensitivity troponin may identify a group of patients with troponin elevation without myocardial infarction, elevated levels of high-sensitivity troponin among patients who present to ED with chest pain is associated with higher rates of mortality and MACE, regardless of index visit diagnosis. [26,27] High-sensitivity troponin should still be used over conventional troponin, as this allows identification of patients who are at high risk and should be followed up more closely, and may be considered of prognostic value for future events even in patients with detectable levels below the 99th percentile or with stable low-level elevations. [28]

Conclusion

In acute MI, patients with hyperuricemia had higher mortality. Serum uric acid levels correlated with Killip classification in acute MI. Serum uric acid can be used as a marker of short term mortality in patients. Hyperuricemia is an indicator of poor prognosis in acute MI. Uric acid is an economical biomarker that is readily, quickly and reliably obtainable, it can be one of the predictable prognostic indicator in acute Myocardial Infarction.

References

1. Cairns C., Kang K. National Hospital Ambulatory Medical Care Survey: 2019.
2. Rubini Gimenez M, Twerenbold R, Reichlin T, Wildi K, Haaf P, Schaefer M, Zellweger C, Moehring B, Stallone F, Sou SM, Mueller M, Denhaerynck K, Mosimann T, Reiter M, Meller B, Freese M, Stelzig C, Klimmeck I, Voegele J, Hartmann B, Rentsch K, Osswald S, Mueller C. Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. Eur Heart J. 2014 Sep 7;35(34):2303-11.
3. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 Apr 7;42(14):1289-1367.
4. Than M, Cullen L, Reid CM, Lim SH, Aldous S, Ardagh MW, Peacock WF, Parsonage WA, Ho HF, Ko HF, Kasliwal RR, Bansal M, Soerianata S, Hu D, Ding R, Hua Q, Seok-Min K, Sritara P, Sae-Lee R, Chiu TF, Tsai KC, Chu FY, Chen WK, Chang WH, Flaws DF, George PM, Richards AM. A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational valida tion study. Lancet. 2011 Mar 26;377(9771): 1077-84.
5. Høilund-Carlsen PF, Johansen A, Vach W, Christensen HW, Møldrup M, Haghfelt T. High probability of disease in angina pectoris patients: is clinical estimation reliable? Can J Cardiol. 2007 Jun;23(8):641-7.
6. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019 Jan 14;40(3):237-269.
7. Katrukha IA. Human cardiac troponin complex. Structure and functions. Biochemi stry (Mosc). 2013 Dec;78(13):1447-65.
8. Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, Lindahl B, Giannitsis E, Hasin Y, Galvani M, Tubaro M, Alpert JS, Biasucci LM, Koenig W, Mueller C, Huber K, Hamm C, Jaffe AS; Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J. 2010 Sep;31(18):2197-204.
9. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med. 1997 Dec 4;337(23):1648-53.
10. Goodacre S, Thokala P, Carroll C, Stevens JW, Leaviss J, Al Khalaf M, Collinson P, Morris F, Evans P, Wang J. Systematic review, meta-analysis and economic modelling of diagnostic strategies for suspected acute coronary syndrome. Health Technol Assess. 2013;17(1): v-vi, 1-188.
11. Reichlin T, Cullen L, Parsonage WA, Greenslade J, Twerenbold R, Moehring B, Wildi K, Mueller S, Zellweger C, Mosimann T, Rubini Gimenez M, Rentsch K, Osswald S, Müller C. Two-hour algorithm for triage toward rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. Am J Med. 2015 Apr;128(4):369-79.e4.
12. Parsonage WA, Greenslade JH, Hammett CJ, Lamanna A, Tate JR, Ungerer JP, Chu K, Than M, Brown AF, Cullen L. Validation of an accelerated high-sensitivity troponin T assay protocol in an Australian cohort with chest pain. Med J Aust. 2014 Feb 17;200(3):161-5.

13. Murray CJ, Lopez AD. Mortality by cause for eight regions of the worls: Global Burden of Disease Study. Lancet. 1997;349(9061):1269 – 76.

14. Gupta R, Mohan I, Narula J. Trends in coronart heart disease epidemiology in India. Ann Glob Health. 2016;82(2):307–15.

15. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107(15): 1991–7.

16. Levya F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18(5):858–65.

17. Longo F, Kasper M. Heart failure and Cor Pulmonale. In: Harrison's Principles of Internal Medicine. New York: Mc Graw Hill; 2011.

18. Holme I, Aastviet AH, Hammar N, Jungner I, Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in apolipoprotein mortality risk study (AMORIS). J Intern Med. 2009;266(6):558–70.

19. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk Factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;37(6):1503–7.

20. Storhaug HM, Norvik JV, Toft I, Eriksen BO, Løchen ML, Zykova S, Solbu M, White S, Chadban S, Jenssen T. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromsø Study. BMC cardiovascular disorders. 2013 Dec;13:1-0.

21. Zalawadiya SK, Veeranna V, Mallikethi-Reddy S, Bavishi C, Lunagaria A, Kottam A, Afonso L. Uric acid and cardiovascular disease risk reclassification: findings from NHANES III. European journal of preventive cardiology. 2015 Apr;22(4):513-8.

22. Otani N, Toyoda S, Sakuma M, Hayashi K, Ouchi M, Fujita T, Anzai N, Tanaka A, Node K, Uemura N, Inoue T. Effects of uric acid on vascular endothelial function from bedside to bench. Hypertension Research. 2018 Nov;41(11):923-31.

23. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003 Jun 1;41(6):1287-93.

24. Ndrepepa G. Uric acid and cardiovascular disease. Clinica chimica acta. 2018 Sep 1;484: 150-63.

25. Pacifico L, Cantisani V, Anania C, Bonaiuto E, Martino F, Pascone R, Chiesa C. Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. European Journal of Endocrinology. 2009 Jan;160(1):45-52.

26. Melki D, Lugnegård J, Alfredsson J, Lind S, Eggers KM, Lindahl B, Jernberg T. Implications of Introducing High-Sensitivity Cardiac Troponin T Into Clinical Practice: Data From the SWEDEHEART Registry. J Am Coll Cardiol. 2015 Apr 28;65(16):1655-1664.

27. Roos A, Bandstein N, Lundbäck M, Hammarsten O, Ljung R, Holzmann MJ. Stable High-Sensitivity Cardiac Troponin T Levels and Outcomes in Patients With Chest Pain. J Am Coll Cardiol. 2017 Oct 31;70(18): 2226-2236.

28. Bonaca MP. Time for a New Strategy for High-Sensitivity Troponin in the Emergency Department. J Am Coll Cardiol. 2017 Oct 31;70(18):2237-2239.